Skip to main contentSkip to navigationSkip to search

Curasight announces new date of the Annual General Meeting and an updated financial calendar 2022

March 9, 2022


Copenhagen, Denmark, 9 March 2022 - Curasight A/S (“Curasight” or the “Company”) announces that the Company’s Annual General Meeting will be held on 27 April 2022 and an updated financial calendar for rest of 2022

The Annual General Meeting of Curasight is planned to be held on 27 April 2022. Consequently, the financial calendar and information on the date of the Annual General Meeting set out in the Annual Report for the financial year 2021 are updated accordingly.

Curasight has thus scheduled the following dates for the remainder of 2022:

Deadline for submission of shareholder proposals to Annual General Meeting
March 15, 2022

Annual General Meeting 2022
April 27, 2022

Interim Report Q1 2022
May 24, 2022

Interim Report First Half 2022
August 25, 2022

Interim Report Q3 2022
November 24, 2022

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel theranostic platform with Positron Emissions Tomography (PET) imaging and Radionuclide Therapy targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis, risk stratification and therapy in multiple cancer types.